Vaccine Wars! The British Are Now Claiming That Their COVID-19 Vaccine By AstraZeneca Is Far More Superior Than The American Pfizer Vaccines!

While the world is already suffering from the escalating COVID-19 pandemic thanks to the incompetency of the WHO, vaccine wars are breaking around the globe with country being nationalistic and claiming that their own manufactured vaccine is better than the next country’s vaccine.

 
The Chinese have been claiming that their Sinovac and Sinopharm vaccines are good while the Russian are claiming that their Sputnik vaccines are far more superior and the now we have the British and Americans engaged in a war with the British using an Oxford University study claiming that their Astrazenaca Vaccine is better than the American Pfizer vaccine.
 
Readers should note that these days, research and published studies can no longer be trusted. Researchers are these days no better than cheap whores as with the right amounts of money, they would distort science and manipulate results to please their clients cum paymasters which are usually the big pharma and their investors. Most prestigious education institutions these days have turned into brothels with some of these big Pharma or even government associated institutions like the U.S NIH being patrons to these institutions and funding them constantly so that the most accommodating 'whores' are retained for their needs!
 
British researchers are now claiming that the effectiveness of the American Pfizer-BioNTech vaccine against COVID-19 declines faster than that of the British AstraZeneca jab.https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf

The study found that "the dynamics of immunity following second doses differed significantly" between Pfizer and AstraZeneca.
 
The team said that Pfizer had "greater initial effectiveness" but saw "faster declines in protection against high viral burden and symptomatic infection", when looking at a period of several months after full vaccination, although rates remained low for both jabs.
 
"The study results suggest that after four to five months effectiveness of these two vaccines would be similar," the scientists added, while stressing that long-term effects need to be studied.
 
However it should be noted that in this case, the study has yet to be published yet even in a preprint server let alone peer reviewed yet but the research team did pay a huge amount of money to a PR firm to get the details out to various mainstream media and wire agencies, off course with monies from which big pharma if we were follow the money trail!
 
The British study team from University of Oxford said that although two doses of the Pfizer BioNTech vaccine appears to have greater effectiveness initially against new COVID-19 infections associated with the Delta variant when compared to the Oxford AstraZeneca jab, but its efficacy also declines faster, preliminary research suggests.
 
The study team said that after four to five months, the level of protection offered by both vaccines is similar, with the AstraZeneca jab maintaining its effectiveness throughout the du ration.
 
The study findings, which have not yet been peer reviewed, also suggest that those infected with the Delta variant after their second jab had similar peak levels of virus to unvaccinated people.
 
The researchers said that although jabs did not eliminate chances of getting COVID-19, they did reduce the risk and remained the most effective way to ensure protection against the Delta variant – which has become dominant in the UK.
 
Professor of medical statistics and epidemiology at the University of Oxford, Sarah Walker, told Thailand Medical News, “We don’t yet know how much transmission can happen from people who get Covid-19 after being vaccinated for example, they may have high levels of virus for shorter periods of time. But the fact that they can have high levels of virus suggests that people who aren’t yet vaccinated may not be as protected from the Delta variant as we hoped. This means it is essential for as many people as possible to get vaccinated, both in the UK and worldwide.”
 
The research was conducted in partnership with the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), looked at data between December 2020 and August 2021 from the Covid-19 Infection Survey.
 
The nasal swab tests from more than 700,000 participants were analyzed from before and after May 17 2021, when Delta became the main variant in the UK.
 
Detailed analysis revealed that for infections with a high viral load, protection a month after the second Pfizer dose was 90% greater than an unvaccinated individual, reducing to 85% after two months and 78% after three.
 
In the case of the AstraZeneca vaccine, the equivalent protection was 67%, 65% and 61%, the researchers said.
 
Senior researcher at the University of Oxford’s Nuffield Department of Population Health, Dr Koen Pouwels said that the team “can be confident” that the numbers “really represent a decline” for the Pfizer vaccine, whereas for AstraZeneca “the differences are compatible with chance, that is there could be no change at all in the protection from AZ”.
 
However he added, “Even with these slight declines in protection against all infections and infections with high viral burden, it’s important to note that overall effectiveness is still very high because we were starting at such a high level of protection. It is also worth highlighting that these data here do not tell us about protection levels against severe disease and hospitalization, which are two very important factors when looking at how well the vaccines are working.”
 
Alarmingly this study shows that although Delta is better at infecting vaccinated people than previous variants, the vaccines still work remarkably well.
 
The study team at Oxford stressed, "Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford-AstraZeneca.”
 
The study team also found that a single dose of the Moderna vaccine had similar or greater effectiveness against the Delta variant as single doses of the other vaccines, but the researchers added that they did not yet have any data on second doses of the US-made jab.
 
The research also suggested that the time between doses did not affect effectiveness in preventing new infections, and that younger people (aged 18-34) had more protection from vaccination than older age groups (35 to 64-year-olds).
 
The study team said they could not comment on what the study might mean for the potential autumn booster campaign, but said that the Joint Committee on Vaccination and Immunisation (JCVI) would be considering the data while making its decision.
 
The NHS officials have geared up to start offering a third coronavirus jab from early September, but are yet to be given the green light to press ahead from the JCVI.
 
Dr Alexander Edwards, associate professor in Biomedical Technology at the University of Reading, who was not involved in the study added, “Overall this study is excellent as it shows that although Delta is better at infecting vaccinated people than previous variants, the vaccines still work remarkably well. There are subtle differences between different vaccine types and some changes over time but they all work brilliantly.”
 
The study examined two groups of more than 300,000 people over 18, first during the period dominated by the Alpha variant, which emerged in Kent, southeast England, and secondly from May 2021 onwards, when the Delta variant has been dominant.
 
It confirmed that vaccines are less effective against Delta, which was first seen in India.
 
The AstraZeneca vaccine is the most widely offered in the UK, while those under 40 are offered Pfizer or Moderna due to blood clotting concerns.
 
It should also be noted that there are unproven speculations and rumours going around that AstraZeneca vaccines produced in different countries have different potencies due to non-standardized manufacturing standards as a result of that, individuals are concerned about the origin of these vaccines and are not accepting AstraZeneca vaccines made in certain countries.Some sources are saying that this is fake news and is not true.

There should also be more hot air coming soon as Thailand, a late bloomer is now also trying to come up with its own COVID-19 vaccine. Already some of ignorant fans from the local university( A university that only ranks 215 in the world. https://www.topuniversities.com/universities/chulalongkorn-university) that is behind the development are the making claims that its vaccine has similar if not greater efficacy that the Pfizer vaccine! (Scary indeed!)
 
For more about COVID-19 Vaccines, keep on logging to Thailand Medical News.